{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:41:46Z","timestamp":1787071306628,"version":"build-2736575974"},"reference-count":78,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n                  <jats:p>Dry eye is a multifactorial condition characterized by tear film instability, leading to visual disturbances and discomfort. In Asia, clinical management often follows a tear film\u2013oriented approach that emphasizes restoring specific tear components, particularly through the use of secretagogues such as diquafosol and rebamipide. These agents promote aqueous and\/or mucin secretion and have been widely adopted in Japan and other Asian countries as frontline therapies for various tear film deficiencies. This review outlines the clinical rationale for secretagogue use and summarizes real-world applications across different settings, including general outpatient care, perioperative management for cataract surgery, and contact lens-related ocular surface disorders. Tear Film\u2013Oriented Diagnosis \u2013 a framework for classifying dry eye subtypes based on tear breakup patterns and identifying deficiencies in aqueous, lipid, or mucin components \u2013 is presented as a practical guide for treatment selection. Evidence from clinical trials and long-term observational studies supports the safety and efficacy of diquafosol and rebamipide in improving tear stability, reducing epithelial damage, and enhancing patient satisfaction. By highlighting regional practice patterns and accumulated clinical experience, this article offers perspectives on effectively integrating secretagogues into dry eye management. These insights may contribute to a broader understanding of individualized, mechanism-based treatment strategies beyond inflammation suppression.<\/jats:p>","DOI":"10.4103\/tjo.tjo-d-25-00110","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T16:01:28Z","timestamp":1762876888000},"page":"526-534","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Integrating secretagogues into clinical dry eye care: Insights from Asian clinical experience"],"prefix":"10.4103","volume":"15","author":[{"given":"Shizuka","family":"Koh","sequence":"first","affiliation":[{"name":"Department of Innovative Visual Science, Osaka University Graduate School of Medicine, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"key":"R1-20251223","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jtos.2017.05.008","article-title":"TFOS DEWS II definition and classification report","volume":"15","author":"Craig","year":"2017","journal-title":"Ocul Surf"},{"key":"R2-20251223","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jtos.2016.09.003","article-title":"New perspectives on dry eye definition and diagnosis:A consensus report by the Asia dry eye society","volume":"15","author":"Tsubota","year":"2017","journal-title":"Ocul Surf"},{"issue":"Suppl 1","key":"R3-20251223","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1097\/ICL.0000000000000643","article-title":"Anew perspective on dry eye classification:Proposal by the Asia dry eye society","volume":"46","author":"Tsubota","year":"2020","journal-title":"Eye Contact Lens"},{"key":"R4-20251223","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/ICL.0000000000001171","article-title":"Exploring new and global therapeutic options for dry eye disease:What you need to know","volume":"51","author":"Koh","year":"2025","journal-title":"Eye Contact Lens"},{"key":"R5-20251223","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0161-6420(99)00176-1","article-title":"Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA phase 3 study group","volume":"107","author":"Sall","year":"2000","journal-title":"Ophthalmology"},{"key":"R6-20251223","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.ophtha.2019.03.050","article-title":"A phase 3, randomized, double-masked study of OTX-101 ophthalmic solution 0.09% in the treatment of dry eye disease","volume":"126","author":"Goldberg","year":"2019","journal-title":"Ophthalmology"},{"key":"R7-20251223","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.ophtha.2019.01.024","article-title":"A clinical phase II study to assess efficacy, safety, and tolerability of waterfree cyclosporine formulation for treatment of dry eye disease","volume":"126","author":"Wirta","year":"2019","journal-title":"Ophthalmology"},{"key":"R8-20251223","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.ophtha.2013.09.015","article-title":"Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease:Results of the OPUS-1 phase 3 study","volume":"121","author":"Sheppard","year":"2014","journal-title":"Ophthalmology"},{"key":"R9-20251223","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ophtha.2021.11.004","article-title":"Efficacy and safety of OC-01 (varenicline solution) nasal spray on signs and symptoms of dry eye disease:The ONSET-2 phase 3 randomized trial","volume":"129","author":"Wirta","year":"2022","journal-title":"Ophthalmology"},{"key":"R10-20251223","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/ICO.0000000000002452","article-title":"Safety of KPI-121 ophthalmic suspension 0.25% in patients with dry eye disease:A pooled analysis of 4 multicenter, randomized, vehicle-controlled studies","volume":"40","author":"Korenfeld","year":"2021","journal-title":"Cornea"},{"key":"R11-20251223","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.ophtha.2022.12.021","article-title":"NOV03 for dry eye disease associated with meibomian gland dysfunction:Results of the randomized phase 3 GOBI study","volume":"130","author":"Tauber","year":"2023","journal-title":"Ophthalmology"},{"key":"R12-20251223","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/ICO.0000000000003097","article-title":"Lotilaner ophthalmic solution, 0.25%, for the treatment of demodex blepharitis:Results of a prospective, randomized, vehicle-controlled, double-masked, pivotal trial (saturn-1)","volume":"42","author":"Yeu","year":"2023","journal-title":"Cornea"},{"key":"R13-20251223","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1167\/iovs.17-23700","article-title":"Tear film-oriented diagnosis and tear film-oriented therapy for dry eye based on tear film dynamics","volume":"59","author":"Yokoi","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R14-20251223","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ajo.2017.05.022","article-title":"Classification of fluorescein breakup patterns:A novel method of differential diagnosis for dry eye","volume":"180","author":"Yokoi","year":"2017","journal-title":"Am J Ophthalmol"},{"key":"R15-20251223","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s12325-012-0033-9","article-title":"Diquafosol ophthalmic solution for dry eye treatment","volume":"29","author":"Nakamura","year":"2012","journal-title":"Adv Ther"},{"key":"R16-20251223","first-page":"1029","article-title":"Stimulatory effect of diquafosol tetrasodium on tear fluid secretion in normal rabbits","volume":"28","author":"Takaoka-Shichijo","year":"2011","journal-title":"Atarashii Ganka (J Eye)"},{"key":"R17-20251223","first-page":"261","article-title":"Effect of diquafosol tetrasodium on MUC5AC secretion by rabbit conjunctival tissues","volume":"28","author":"Takaoka-Shichijo","year":"2011","journal-title":"Atarashii Ganka (J Eye)"},{"key":"R18-20251223","doi-asserted-by":"crossref","first-page":"878","DOI":"10.3109\/02713683.2014.967871","article-title":"Diquafosol tetrasodium increases the concentration of mucin-like substances in tears of healthy human subjects","volume":"40","author":"Shigeyasu","year":"2015","journal-title":"Curr Eye Res"},{"key":"R19-20251223","first-page":"425","article-title":"Stimulatory effect of diquafosol tetrasodium on the expression of membrane-binding mucin genes in cultured human corneal epithelial cells","volume":"28","author":"Takaoka-Shichijo","year":"2011","journal-title":"Atarashii Ganka (J Eye)"},{"key":"R20-20251223","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3390\/jcm11020367","article-title":"Adherence to eye drops usage in dry eye patients and reasons for non-compliance:A web-based survey","volume":"11","author":"Uchino","year":"2022","journal-title":"J Clin Med"},{"key":"R21-20251223","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1097\/01.ico.0000133993.14768.a9","article-title":"Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye","volume":"23","author":"Tauber","year":"2004","journal-title":"Cornea"},{"key":"R22-20251223","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1016\/j.ophtha.2012.04.010","article-title":"Efficacy and safety of diquafosol ophthalmic solution in patients with dry eye syndrome:A Japanese phase 2 clinical trial","volume":"119","author":"Matsumoto","year":"2012","journal-title":"Ophthalmology"},{"key":"R23-20251223","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1136\/bjophthalmol-2011-301448","article-title":"A randomised, double-masked comparison study of diquafosol versus sodium hyaluronate ophthalmic solutions in dry eye patients","volume":"96","author":"Takamura","year":"2012","journal-title":"Br J Ophthalmol"},{"key":"R24-20251223","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1007\/s10384-013-0251-y","article-title":"Long-term results of treatment with diquafosol ophthalmic solution for aqueous-deficient dry eye","volume":"57","author":"Koh","year":"2013","journal-title":"Jpn J Ophthalmol"},{"key":"R25-20251223","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1097\/ICO.0b013e3182930b1d","article-title":"Effects of diquafosol sodium eye drops on tear film stability in short BUT type of dry eye","volume":"32","author":"Shimazaki-Den","year":"2013","journal-title":"Cornea"},{"key":"R26-20251223","doi-asserted-by":"crossref","first-page":"e671","DOI":"10.1111\/aos.12443","article-title":"Effect of diquafosol ophthalmic solution on the optical quality of the eyes in patients with aqueous-deficient dry eye","volume":"92","author":"Koh","year":"2014","journal-title":"Acta Ophthalmol"},{"key":"R27-20251223","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1136\/bjophthalmol-2014-306084","article-title":"A randomised, parallel-group comparison study of diquafosol ophthalmic solution in patients with dry eye in China and Singapore","volume":"99","author":"Gong","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"R28-20251223","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s12325-019-01188-x","article-title":"Long-term safety and effectiveness of diquafosol for the treatment of dry eye in a real-world setting:A prospective observational study","volume":"37","author":"Ohashi","year":"2020","journal-title":"Adv Ther"},{"key":"R29-20251223","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1038\/eye.2012.166","article-title":"Clinical evaluation of the additive effect of diquafosol tetrasodium on sodium hyaluronate monotherapy in patients with dry eye syndrome:A prospective, randomized, multicenter study","volume":"26","author":"Kamiya","year":"2012","journal-title":"Eye (Lond)"},{"key":"R30-20251223","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1097\/ICO.0000000000000213","article-title":"Additive effect of preservative-free sodium hyaluronate 0.1% in treatment of dry eye syndrome with diquafosol 3% eye drops","volume":"33","author":"Hwang","year":"2014","journal-title":"Cornea"},{"key":"R31-20251223","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/APO.0000000000000493","article-title":"First diquafosol treatment for dry eye:10-year follow-up","volume":"12","author":"Koh","year":"2023","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"R32-20251223","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/ICL.0000000000001071","article-title":"Gal\u00e1pagosization:Diquafosol for dry eyes","volume":"50","author":"Koh","year":"2024","journal-title":"Eye Contact Lens"},{"key":"R33-20251223","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1007\/s10620-008-0507-4","article-title":"Rebamipide, a cytoprotective drug, increases gastric mucus secretion in human:Evaluations with endoscopic gastrin test","volume":"54","author":"Iijima","year":"2009","journal-title":"Dig Dis Sci"},{"key":"R34-20251223","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1586\/egh.10.25","article-title":"Rebamipide:A gastrointestinal protective drug with pleiotropic activities","volume":"4","author":"Naito","year":"2010","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"R35-20251223","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/0014-2999(87)90649-2","article-title":"Gastric mucosal protection by OPC-12759, a novel antiulcer compound, in the rat","volume":"142","author":"Yamasaki","year":"1987","journal-title":"Eur J Pharmacol"},{"key":"R36-20251223","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/01.ico.0000126436.25751.fb","article-title":"Rebamipide increases the amount of mucin-like substances on the conjunctiva and cornea in the N-acetylcysteine-treated in vivo model","volume":"23","author":"Urashima","year":"2004","journal-title":"Cornea"},{"key":"R37-20251223","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1001\/jamaophthalmol.2014.431","article-title":"Effect of topical rebamipide on human conjunctival goblet cells","volume":"132","author":"Kase","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"R38-20251223","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1089\/jop.2011.0142","article-title":"Rebamipide increases the mucin-like glycoprotein production in corneal epithelial cells","volume":"28","author":"Takeji","year":"2012","journal-title":"J Ocul Pharmacol Ther"},{"key":"R39-20251223","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3109\/02713683.2013.834939","article-title":"Regulation of human corneal epithelial mucins by rebamipide","volume":"39","author":"Itoh","year":"2014","journal-title":"Curr Eye Res"},{"key":"R40-20251223","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1167\/iovs.17-23685","article-title":"Contact lens-associated dry eye disease:Recent advances worldwide and in Japan","volume":"59","author":"Kojima","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R41-20251223","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.ophtha.2012.12.022","article-title":"A randomized, multicenter phase 3 study comparing 2% rebamipide (OPC-12759) with 0.1% sodium hyaluronate in the treatment of dry eye","volume":"120","author":"Kinoshita","year":"2013","journal-title":"Ophthalmology"},{"key":"R42-20251223","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1016\/j.ophtha.2012.06.052","article-title":"Rebamipide (OPC-12759) in the treatment of dry eye:A randomized, double-masked, multicenter, placebo-controlled phase II study","volume":"119","author":"Kinoshita","year":"2012","journal-title":"Ophthalmology"},{"key":"R43-20251223","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1097\/ICO.0b013e318294f97e","article-title":"Effect of rebamipide ophthalmic suspension on optical quality in the short break-up time type of dry eye","volume":"32","author":"Koh","year":"2013","journal-title":"Cornea"},{"key":"R44-20251223","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12886-015-0040-0","article-title":"Effectiveness and relevant factors of 2% rebamipide ophthalmic suspension treatment in dry eye","volume":"15","author":"Ueda","year":"2015","journal-title":"BMC Ophthalmol"},{"key":"R45-20251223","doi-asserted-by":"crossref","first-page":"15210","DOI":"10.1038\/s41598-017-13121-9","article-title":"A prospective, randomized trial of two mucin secretogogues for the treatment of dry eye syndrome in office workers","volume":"7","author":"Shimazaki","year":"2017","journal-title":"Sci Rep"},{"key":"R46-20251223","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1186\/s12886-023-03004-1","article-title":"Efficacy and safety of 1% and 2% rebamipide clear solution in dry eye disease:A multicenter randomized trial","volume":"23","author":"Eom","year":"2023","journal-title":"BMC Ophthalmol"},{"key":"R47-20251223","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/ICL.0000000000001101","article-title":"Clinical efficacy of 2% rebamipide in patients with video display terminal-associated dry eye disease:A prospective, randomized, double-blinded study","volume":"50","author":"Lee","year":"2024","journal-title":"Eye Contact Lens"},{"key":"R48-20251223","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.2147\/OPTH.S47445","article-title":"Topical rebamipide improves the ocular surface in mild lagophthalmos","volume":"7","author":"Itakura","year":"2013","journal-title":"Clin Ophthalmol"},{"key":"R49-20251223","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.ajo.2013.12.027","article-title":"Topical rebamipide treatment for superior limbic keratoconjunctivitis in patients with thyroid eye disease","volume":"157","author":"Takahashi","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"R50-20251223","first-page":"1369","article-title":"Efficacy of rebamipide ophthalmic solution for treatment resistant filamentary keratitis:Three case reports","volume":"31","author":"Ikegawa","year":"2014","journal-title":"Atarashii Ganka (J Eye)"},{"key":"R51-20251223","doi-asserted-by":"crossref","first-page":"4927","DOI":"10.1167\/iovs.13-12409","article-title":"Effect of instillation of eyedrops for dry eye on optical quality","volume":"54","author":"Koh","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R52-20251223","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.ajo.2013.11.010","article-title":"A multicenter, open-label, 52-week study of 2% rebamipide (OPC-12759) ophthalmic suspension in patients with dry eye","volume":"157","author":"Kinoshita","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"R53-20251223","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1136\/bjophthalmol-2018-312333","article-title":"Effects of tear film dynamics on quality of vision","volume":"102","author":"Koh","year":"2018","journal-title":"Br J Ophthalmol"},{"key":"R54-20251223","first-page":"489","article-title":"Dry eye clinical practice guidelines","volume":"123","year":"2019","journal-title":"J Jpn Ophthalmol Soc"},{"key":"R55-20251223","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jcrs.2019.03.023","article-title":"An algorithm for the preoperative diagnosis and treatment of ocular surface disorders","volume":"45","author":"Starr","year":"2019","journal-title":"J Cataract Refract Surg"},{"issue":"Suppl 1","key":"R56-20251223","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1097\/ICO.0000000000000998","article-title":"Mechanisms of visual disturbance in dry eye","volume":"35","author":"Koh","year":"2016","journal-title":"Cornea"},{"key":"R57-20251223","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1167\/iovs.17-23500","article-title":"Irregular astigmatism and higher-order aberrations in eyes with dry eye disease","volume":"59","author":"Koh","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R58-20251223","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/j.jcrs.2015.01.016","article-title":"Effect of tear osmolarity on repeatability of keratometry for cataract surgery planning","volume":"41","author":"Epitropoulos","year":"2015","journal-title":"J Cataract Refract Surg"},{"key":"R59-20251223","doi-asserted-by":"crossref","first-page":"710","DOI":"10.3390\/jcm11030710","article-title":"Influence of dry eye disease on the measurement repeatability of corneal curvature radius and axial length in patients with cataract","volume":"11","author":"Hiraoka","year":"2022","journal-title":"J Clin Med"},{"key":"R60-20251223","doi-asserted-by":"crossref","first-page":"e303","DOI":"10.1097\/OPX.0000000000000490","article-title":"Intraocular scattering after instillation of diquafosol ophthalmic solution","volume":"92","author":"Kobashi","year":"2015","journal-title":"Optom Vis Sci"},{"key":"R61-20251223","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1007\/s40123-024-00940-z","article-title":"Effect of long-acting diquafosol sodium on astigmatism measurement repeatability in preoperative cataract cases with dry eyes:A multicenter prospective study","volume":"13","author":"Teshigawara","year":"2024","journal-title":"Ophthalmol Ther"},{"key":"R62-20251223","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s40123-022-00457-3","article-title":"The effect of rebamipide on refractive accuracy of cataract surgery in patients with dry eye","volume":"11","author":"Teshigawara","year":"2022","journal-title":"Ophthalmol Ther"},{"key":"R63-20251223","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2147\/OPTH.S122542","article-title":"Effects of 3% diquafosol sodium ophthalmic solution on higher-order aberrations in patients diagnosed with dry eye after cataract surgery","volume":"11","author":"Inoue","year":"2017","journal-title":"Clin Ophthalmol"},{"key":"R64-20251223","doi-asserted-by":"crossref","first-page":"529","DOI":"10.2147\/OPTH.S129178","article-title":"Influence on ocular surface after cataract surgery and effect of topical diquafosol on postoperative dry eye:A multicenter prospective randomized study","volume":"11","author":"Miyake","year":"2017","journal-title":"Clin Ophthalmol"},{"key":"R65-20251223","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ajo.2015.12.002","article-title":"Clinical effects and safety of 3% diquafosol ophthalmic solution for patients with dry eye after cataract surgery:A randomized controlled trial","volume":"163","author":"Park","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"R66-20251223","first-page":"1363","article-title":"Effect of 2% rebamipide ophthalmic suspension on perioperative period of cataract surgery in dry eye patients","volume":"33","author":"Inoue","year":"2016","journal-title":"Atarashii Ganka (J Eye)"},{"key":"R67-20251223","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1007\/s40123-022-00523-w","article-title":"Impact of perioperative dry eye treatment with rebamipide versus artificial tears on visual outcomes after cataract surgery in Japanese population","volume":"11","author":"Teshigawara","year":"2022","journal-title":"Ophthalmol Ther"},{"key":"R68-20251223","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ajo.2017.06.016","article-title":"Conjunctival goblet cell density following cataract surgery with diclofenac versus diclofenac and rebamipide:A randomized trial","volume":"181","author":"Kato","year":"2017","journal-title":"Am J Ophthalmol"},{"key":"R69-20251223","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1167\/iovs.13-13074","article-title":"The TFOS international workshop on contact lens discomfort:Report of the definition and classification subcommittee","volume":"54","author":"Nichols","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R70-20251223","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1097\/APO.0000000000000329","article-title":"Contact lens wear and dry eye:Beyond the known","volume":"9","author":"Koh","year":"2020","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"R71-20251223","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1097\/OPX.0b013e318269c90d","article-title":"Contact lens dry eye questionnaire-8 (CLDEQ-8) and opinion of contact lens performance","volume":"89","author":"Chalmers","year":"2012","journal-title":"Optom Vis Sci"},{"key":"R72-20251223","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.clae.2016.04.005","article-title":"Cutoff score and responsiveness of the 8-item contact lens dry eye questionnaire (CLDEQ-8) in a large daily disposable contact lens registry","volume":"39","author":"Chalmers","year":"2016","journal-title":"Cont Lens Anterior Eye"},{"key":"R73-20251223","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.clae.2019.03.002","article-title":"Translation and validation of the 8-item contact lens dry eye questionnaire (CLDEQ-8) among Japanese soft contact lens wearers:The J-CLDEQ-8","volume":"42","author":"Koh","year":"2019","journal-title":"Cont Lens Anterior Eye"},{"key":"R74-20251223","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1097\/ICL.0000000000000134","article-title":"Prominent decrease of tear meniscus height with contact lens wear and efficacy of eye drop instillation","volume":"41","author":"Nagahara","year":"2015","journal-title":"Eye Contact Lens"},{"key":"R75-20251223","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1097\/OPX.0000000000000877","article-title":"Diquafosol for soft contact lens dryness:Clinical evaluation and tear analysis","volume":"93","author":"Shigeyasu","year":"2016","journal-title":"Optom Vis Sci"},{"key":"R76-20251223","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/ICL.0000000000000283","article-title":"Diquafosol ophthalmic solution increases pre- and postlens tear film during contact lens wear in rabbit eyes","volume":"43","author":"Nagahara","year":"2017","journal-title":"Eye Contact Lens"},{"key":"R77-20251223","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.clae.2017.12.016","article-title":"The effect of rebamipide ophthalmic suspension on ocular surface mucins in soft contact lens wearers","volume":"41","author":"Shigeyasu","year":"2018","journal-title":"Cont Lens Anterior Eye"},{"issue":"Suppl 2","key":"R78-20251223","doi-asserted-by":"crossref","first-page":"S137","DOI":"10.1097\/ICL.0000000000000438","article-title":"Efficacy of rebamipide instillation for contact lens discomfort with dry eye","volume":"44","author":"Igarashi","year":"2018","journal-title":"Eye Contact Lens"}],"container-title":["Taiwan Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/tjo.TJO-D-25-00110","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:44:24Z","timestamp":1787067864000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/tjo.TJO-D-25-00110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":78,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/tjo.tjo-d-25-00110","relation":{},"ISSN":["2211-5056","2211-5072"],"issn-type":[{"value":"2211-5056","type":"print"},{"value":"2211-5072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"2025-07-05","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-25","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}